BofA Merrill Lynch,
The shares are being offered by bluebird bio pursuant to an
automatically effective shelf registration statement that was previously
filed with the
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such state or jurisdiction.
About bluebird bio, Inc.
With its lentiviral-based gene therapy and gene editing capabilities,
bluebird bio has built an integrated product platform with broad
potential application to severe genetic diseases and T cell-based
immunotherapy. bluebird bio’s clinical programs include Lenti-D™,
currently in a Phase 2/3 study, called the Starbeam Study, for the
treatment of childhood cerebral adrenoleukodystrophy, and LentiGlobin®,
currently in three clinical studies: a global Phase 1/2 study, called
the Northstar Study, for the treatment of beta-thalassemia major; a
single-center Phase 1/2 study in
bluebird bio has operations in
Forward-Looking Statements
This release contains “forward-looking statements” within the meaning
of the Private Securities Litigation Reform Act of 1995, including
statements regarding the anticipated final terms, timing and completion
of the proposed offering, and bluebird bio’s existing product candidates
and research programs. Any forward-looking statements are based on
management’s current expectations of future events and are subject to a
number of risks and uncertainties that could cause actual results to
differ materially and adversely from those set forth in or implied by
such forward-looking statements. These risks and uncertainties include,
but are not limited to, risks and uncertainties related to market
conditions and satisfaction of customary closing conditions related to
the proposed public offering, that the preliminary results from our
clinical trials will not continue or be repeated in our ongoing clinical
trials, the risk that previously conducted studies involving similar
product candidates will not be repeated or observed in ongoing or future
studies involving current product candidates, the risk of cessation or
delay of any of the ongoing or planned clinical studies and/or our
development of our product candidates, the risk of a delay in the
enrollment of patients in our clinical studies, the risk that our
collaboration with
View source version on businesswire.com: http://www.businesswire.com/news/home/20150623006535/en/
Source: bluebird bio, Inc.
Investor Relations
bluebird bio, Inc.
Manisha Pai,
617-245-2107
mpai@bluebirdbio.com
or
Media
Contact
Pure Communications, Inc.
Dan Budwick, 973-271-6085